PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Serevent for asthma: patients at a greater risk of non-fatal serious adverse events


People with asthma who regularly use Salmeterol ( Serevent ) are at a greater risk of non-fatal serious adverse events than those using placebo. This conclusion was arrived at by a team of Cochrane Researchers who drew together data from 26 trials involving 62,630 patients.
The researchers found that over a four to six month period, for every thousand people treated for asthma there were 45 who suffered a serious adverse event on regular Salmeterol, compared to only 40 if a placebo inhaler was given.

Salmeterol is a long-acting beta2-agonist. It is inhaled by people with asthma twice daily, and relieves symptoms for up to 12 hours. It is generally recommended for use along with corticosteroid inhalers.

Over the last decade some researchers and practitioners have expressed anxieties that although Salmeterol can relieve asthma symptoms, it could cause long-term problems.

" We found that the biggest increase in risk was seen in people with asthma who were not taking inhaled corticosteroids; however, there is no guarantee that inhaled corticosteroids abolish the risk all together," says lead researcher Christopher Cates who works in Community Health Sciences at St George's, London, UK.

The authors recommend that people should follow the manufacturer's advice not to increase the dose of Salmeterol during an exacerbation. Furthermore regular Salmeterol should not be used as an alternative to inhaled corticosteroids. Benefits and risks both need to be considered before embarking on long term treatment with regular Salmeterol.

Source: Wiley-Blackwell, 2008

XagenaMedicine_2008



Indietro